FDA Approves EVRYSDI — Genentech, Inc.

# FDA Approves Genentech's EVRYSDI (risdiplam) for Spinal Muscular Atrophy Genentech announced FDA approval of EVRYSDI (risdiplam), an oral treatment for spinal muscular atrophy, positioning the company to capture significant market share in the SMA segment currently dominated by Biogen's Spinraza and Novartis's Zolgensma. The oral formulation and at-home administration capability of EVRYSDI could reshape competitive dynamics and treatment patterns in the rare disease market, potentially